title: Evaluation of ¹⁷⁷Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy.
abstract: 177Lu-EDTMP is currently being investigated as a potential agent for providing palliative care to the patients suffering from bone pain due to metastatic skeletal carcinoma. The present article describes the evaluation of 177Lu-EDTMP complex in four different canine patients with different types of primary and metastatic skeletal lesions with respect to its pharmacokinetic properties, dosimetry and therapeutic efficacy. The dogs were treated with a dose of ~44.4 MBq (1.2 mCi) per kg body weight of 177Lu-EDTMP, synthesized in-house with high radiochemical purity (98.8 ± 0.4 %) and excellent in vitro stability. The radiopharmaceutical showed favourable pharmacokinetic properties, such as, preferential accumulation at skeletal lesion sites and fast clearance from blood and other non-target organs through urinary route. The administered dose of the radiopharmacutical showed excellent therapeutic efficacy in case of a dog suffering from skeletal metastasis originating from primary tumor elsewhere. On the other hand, two of the remaining three patients with primary bone cancer showed stable disease intially with palliative effect. The fourth patient having metal implant induced osteosarcoma with severe limb oedema did not show any response to the treatment.
authors.affiliation: Bhabha Atomic Research Centre, Department of Atomic Energy, Trombay, Mumbai - 400085, India. sudipta@barc.gov.in.
authors.forename: Sudipta
authors.initials: S
authors.lastname: Chakraborty
authors.forename: Lajos
authors.initials: L
authors.lastname: Balogh
authors.forename: Tapas
authors.initials: T
authors.lastname: Das
authors.forename: András
authors.initials: A
authors.lastname: Polyák
authors.forename: Gábor
authors.initials: G
authors.lastname: Andócs
authors.forename: Domokos
authors.initials: D
authors.lastname: Máthé
authors.forename: Réka
authors.initials: R
authors.lastname: Király
authors.forename: Julianna
authors.initials: J
authors.lastname: Thuróczy
authors.forename: Pradip R
authors.initials: PR
authors.lastname: Chaudhari
authors.forename: Gyozo A
authors.initials: GA
authors.lastname: Jánoki
authors.forename: Gergely
authors.initials: G
authors.lastname: Jánoki
authors.forename: Sharmila
authors.initials: S
authors.lastname: Banerjee
authors.forename: M R A
authors.initials: MR
authors.lastname: Pillai
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary; D004285:Dogs; D005260:Female; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D012516:Osteosarcoma / Q000473:pathology / Q000532:radiotherapy; D011868:Radioisotopes / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011874:Radiometry; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014018:Tissue Distribution
chemical_list: D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C119503:lutetium ethylenediaminetetramethylene phosphonic acid